



## Kim-Son Nguyen

Adjunct Clinical Assistant Professor, Medicine - Oncology

### Bio

---

#### BIO

Dr. Kim-Son H. Nguyen obtained his Bachelor of Arts degree from Harvard College, with a concentration in genetics, his Doctor of Medicine from Harvard Medical School, and Master of Public Administration from the Harvard Kennedy School of Government before becoming a faculty member of Harvard Medical School. He then completed his fellowship in hematology and oncology at Stanford University School of Medicine and Stanford Cancer Institute. While maintaining an active clinical practice at Palo Alto Medical Foundation, Dr. Nguyen is an adjunct clinical assistant professor of medicine at Stanford University School of Medicine, with research interests including the molecular epidemiology of lung cancer, cancer screening, cancer therapeutics, and cancer care delivery.

With a unique training and extensive experience in cancer genetics, clinical research, and public policy, Dr. Nguyen has been involved in improving cancer care globally for many years. A former director of the American Society of Clinical Oncology International Program in Vietnam, he is passionate about bringing the latest oncology knowledge to cancer-treating health care providers in resource-limited settings, improving cancer care in disadvantaged patient populations, and promoting clinical research in developing countries.

#### PROFESSIONAL EDUCATION

- Hematology-Oncology Fellowship, Stanford University School of Medicine (2014)
- Internal Medicine Residency, Beth Israel Deaconess Medical Center, Harvard Medical School (2011)
- Doctor of Medicine, Harvard Medical School (2007)
- Master of Public Administration, Harvard Kennedy School of Government (2007)
- Bachelor of Arts, Harvard College (2002)

### Publications

---

#### PUBLICATIONS

- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam** *JOURNAL OF GLOBAL ONCOLOGY*  
Nguyen, K. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, Phan Canh Duy, Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.  
2018; 4
- **Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.** *Journal of global oncology*  
Nguyen, K. H., Stehr, H., Zhou, L., Nguyen, A., Hiep, P. N., Van Cau, N., Duy, P. C., Thorp, R., Wakelee, H. A., Diehn, M., Neal, J. W.  
2018: 1–9
- **Review of the current targeted therapies for non-small-cell lung cancer.** *World journal of clinical oncology*  
Nguyen, K. H., Neal, J. W., Wakelee, H.

2014; 5 (4): 576-587

- **Review of the current targeted therapies for non-small-cell lung cancer** *WORLD JOURNAL OF CLINICAL ONCOLOGY*  
Nguyen, K. H., Neal, J. W., Wakelee, H.  
2014; 5 (4): 576-87
- **Assessment of patients' satisfaction of an innovative oncology telemedicine clinic.**  
Nguyen, K., El-Masry, M., Tham, M., Howard, L., Ventura, R., Chwick, K., Das, M.  
AMER SOC CLINICAL ONCOLOGY.2014
- **Germline Mutations in Driver Oncogenes and Inherited Lung Cancer Risk Independent of Smoking History.** *Journal of the National Cancer Institute*  
Oxnard, G. R., Nguyen, K. H., Costa, D. B.  
2013
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**  
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2013: S208-S209
- **First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.** *Biologics : targets & therapy*  
Nguyen, K. H., Neal, J. W.  
2012; 6: 337-345
- **First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors** *BIOLOGICS-TARGETS & THERAPY*  
Nguyen, K. H., Neal, J. W.  
2012; 6: 337-45
- **Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.** *Journal of oncology practice / American Society of Clinical Oncology*  
Nguyen, K. H., Sanford, R. A., Huberman, M. S., Goldstein, M. A., McDonald, D. M., Farquhar, M., Gangadharan, S. P., Kent, M. S., Michaud, G., Majid, A., Berman, S. M., Aronovitz, J. A., Nedea, et al  
2012; 8 (1): 57-62
- **Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.** *Journal of thoracic disease*  
Britt, G. J., Gaughan, E. M., Nguyen, K. H., Warner, J. L., Goldstein, M. A., Huberman, M. S., Costa, D. B.  
2011; 3 (2): 141-143
- **Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway** *CLINICAL LUNG CANCER*  
Nguyen, K. H., Kobayashi, S., Costa, D. B.  
2009; 10 (4): 281-289
- **Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib** *CLINICAL CANCER RESEARCH*  
Costa, D. B., Nguyen, K. H., Cho, Y. C., Sequist, L. V., Jackman, D. M., Riely, G., Yeap, B. Y., Halmos, B., Kim, J. H., Jaenne, P. A., Huberman, M. S., Pao, W., Tenen, et al  
2008; 14 (21): 7060-7067